Image

Biotronik has received US Food and Drug Administration (FDA) approval to expand its ongoing ProMRI trial, allowing patients enrolled in Phase C of the trial to receive full-body scans, and include patients with DX implantable cardioverter defibrillators (ICDs) in the study for the first time.

ProMRI trial’s Phase C is the final phase in a series of MRI compatibility trials conducted by the company in rapid succession. Phase A and Phase B of the ProMRI trial assessed safety of the Entovis pacemaker systems during MRI scans.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Based on results from Phase A of the ProMRI trial, the FDA has approved the Entovis systems for MRI scans with an exclusion zone in May.

Nearing completion, Phase B expanded the ProMRI trial to assess the safety of Entovis pacemaker systems for full-body scans, including cardiac and thoracic spinal scans. Biotronik is expected to submit data from Phase B to the FDA in the near future.

"The Biotronik-sponsored trial has been enrolling patients since March 2013."

Biotronik obtained CE Mark approval for its implantable cardioverter defibrillator in 2011 for use in a magnetic resonance imaging (MRI) scanner.

See Also:

The ProMRI trial is the next step in making this technology widely available in the US. The Biotronik-sponsored trial has been enrolling patients since March 2013.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Biotronik claims that the DX ICD system, launched in the US in 2013, provides physicians with the complete diagnostic capabilities of a dual-chamber ICD, including atrial sensing and advanced proven shock reduction algorithms with only a single lead.

Biotronik clinical studies vice-president Kevin Mitchell said that the company is committed to extending its ProMRI technology to as many patients as possible.

"We were the first company to offer ICD patients in the US MRI access, and remain the only company that provides single-chamber pacemaker patients access to this diagnostic tool," Mitchell said.

Image: Biotronik’s Entovis single-chamber pacemaker with ProMRI technology. Photo: courtesy of Biotronik, Inc.